Podcasts about Lamanna

Seconds out, round 250! Join Kam & Flowz as they tackle this weeks hot boxing topics! Charlo vs LaManna review (2:25) Plant vs Reséndiz review (16:25) Wardley, Keyshawn, Opetaia and Nakatani in action (30:05) Get involved with the discussion on Twitter using the hashtag #StrapSZN Instagram: @strapsznpodcast Twitter: @strapsznpod We are available on all good streaming platforms. Hit the url below to get direct links to all our streaming pages. Give us a follow, leave us a review and connect with us! https://allmylinks.com/strapsznpodcast

On this segment of "Real Talk", the Ring Gang crew preview Jermall Charlo vs Cornflake Lamanna & Caleb Plant vs Armando Resendiz 

On this segment of "Real Talk", the Ring Gang crew preview Jermall Charlo vs Cornflake Lamanna & Caleb Plant vs Armando Resendiz

Canadian actor Noah Lamanna stars as Kat in the new season of the hit HBO show “The Last of Us.” Noah joins Tom Power to talk about the moment they found out they'd be on one of the biggest shows on TV, what it's like working with Pedro Pascal and Bella Ramsey, and how the film and TV industry has evolved for non-binary actors.

Noah Lamanna is a Toronto-based actor with a background in musical theatre, puppetry and drag performance. In 2023, they played the lead role of Eli in John Tiffany's production of Let the Right One In at Berkeley Repertory Theatre. Noah is best known for their roles as Chief Jay on Star Trek: Strange New Worlds, and Dev on Beacon 23. They have also made apparances on Shelved, EZRA, Ghostwriter and The Umbrella Academy. Noah can currently be seen on season two of HBO's hit post-apocalyptic drama “The Last of Us”. They portray Kat, who dated Ellie (Bella Ramsey) before the events of “The Last of Us”, Part II.   Based on the hit video game franchise by Naughty Dog, the series is set 20 years after a fungal pandemic transforms its hosts into zombie-like creatures, collapsing society. The second season, adapting “The Last of Us”, Part II (2020), picks up five years after the first season's events.   Additionally, Noah will appear in season three of Netflix's “Ginny & Georgia” (premiering June 5, 2025) as Tris, a brainy skateboarder and peer tutor who is a close friend of Marcus (Felix Mallard) and Silver (Katelyn Wells).   Want to watch: YouTube Meisterkhan Pod. (Please Subscribe)

In today's episode, we had the pleasure of speaking with Nicole Lamanna, MD, about patient selection considerations for the use of pirtobrutinib (Jaypirca) in the management of chronic lymphocytic leukemia (CLL). Dr Lamanna is a hematologic oncologist at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center in New York, New York. In our exclusive interview, Dr Lamanna discussed how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in patients with CLL. She also highlighted important clinical features that guide the use of noncovalent BTK inhibitors—including sequencing strategies following covalent BTK and BCL-2 inhibitors, and emphasized the importance of balancing treatment efficacy with tolerability to optimize long-term disease management in CLL.

#jermallcharlo #thomaslamanna #premierboxingchampions ️️️☎️Jermall Charlo and Thomas LaManna Exchange Words. Charlo Says LaManna Dying To Be “BLACK”

In this month's episode, we learn about Camp Woodland, a summer camp that existed in Phoenicia, NY from 1939-1962. Among many of the summer camp settings Pete visited during the 1940s and ‘50s, Woodland was a space Pete visited with regular frequency, and spent much time making music with campers over the course of several decades. As we go in depth with today, Pete's time spent at Woodland would be uniquely impactful for many people, ranging from the Folk Festivals of the Catskills and song collecting to Pete learning Guantanamera from a Cuban counselor in 1962. To learn more about all this, we spoke with two former attendees of the camp, Bill Horne and Pat Lamanna.

#calebplant #jermallcharlo #ThomasLaManna ️️️☎️Plant Vs Resendiz Charlo Vs Lamanna May 31; Plan For A Fall Fight If Both Win

Nicky Lamanna studied kinesiology, anatomy & nutrition. Working through his own health issues, he and his brother, Nathan, developed a philosophy for optimal health through a holistic approach, and went into business together, creating the online company, Mitigate Stress. To learn more please visit mitigatestress.com

In today's episode, supported by BeiGene, Alexey Danilov, MD, PhD, hosted a discussion with Nicole Lamanna, MD, about the use of zanubrutinib (Brukinsa) in patients with chronic lymphocytic leukemia (CLL). Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, the medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma at the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Dr Lamanna is an associate clinical professor of medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division at the Columbia University Herberg Irving Comprehensive Cancer Center in New York, New York.  In our exclusive interview, Drs Danilov and Lamanna discussed key efficacy data from the final comparative analysis of the phase 3 ALPINE trial (NCT03734016) in patients with relapsed/refractory CLL, zanubrutinib-associated toxicities to consider when using this agent, and what the future looks like for BTK inhibitor–based therapy in CLL.

U Guys, a true triple threat, and Seussical's original Gertrude McFuzz, Janine LaManna is here! This week's BroadwayWorld Recap is a short and sweet little roundup of Bway news. Then I am joined by a true Bway legend, Janine LaManna! From standing by for Chita Rivera in Kiss of the Spider Woman, to originating the role of Gertrude McFuzz in Broadway's Seussical, Janine has truly done it all. She made her Broadway debut as Evelyn Nesbit in Ragtime alongside the original company, and eventually went on to work with such legends as Anne Reinking and Harold Prince. She shares about her experience of being the wife of a military officer and traveling the country with her family living in new places, simultaneously being a mother and continuing to work as a performer. We talk about her time playing Nickie in the Broadway revival of Sweet Charity with Christina Applegate, as well as replacing Bway star Sutton Foster as Janet Van De Graaff in the original Broadway production of The Drowsy Chaperone. Her other Bway credits include Swing!, Kiss Me, Kate, and The Look of Love. A true triple threat, Janine's talent is only matched by her grace, humility, and humor. U don't wanna miss this episode! Follow the pod on Instagram: @ohmypoduguys Learn more about your ad choices. Visit megaphone.fm/adchoices

FOUR ACTIONABLE TAKEAWAYS Multi Single-Threading: After a big team meeting, send individual follow-up messages to key stakeholders. This helps build relationships without asking for anything, creating future points of contact. Daily Pipeline Review: Every day, look at your deals and think of specific actions to increase your chances of winning, maintaining daily momentum across opportunities. Win One Stakeholder at a Time: Focus on winning over stakeholders one by one at different stages—manager during discovery, director during the demo, and VP at the big team meeting. Structured Sales Cycle: Brian's sales process follows a clear path: discovery, demo, big team demo, pilot, and finally commercial negotiation. PATH TO PRESIDENT'S CLUB Senior Mid-Market Account Executive @ Gong Mid-Market Account Executive @ Gong Commercial Account Executive @ Gong Senior Commercial Account Executive @ Gong Enterprise Account Executive @ BrightEdge RESOURCES DISCUSSED Join our weekly newsletter Things you can steal

“One of the most important elements of copilots going forward is going to be the context you make available to it. Everybody wants a copilot to understand them,” says Microsoft Corporate Vice President of Business and Industry Copilot, Charles Lamanna. Speaking with Anurag Rana, Bloomberg Intelligence's senior technology analyst, in this Tech Disruptors podcast episode, Lamanna highlights the fundamental construction of copilots, the different models they use, how customers can fine-tune them further in Copilot Studio and how this progresses the company to the vision of a fully autonomous CRM software. The two also discuss automation in the context of the Power Platform and what these technological advancements mean for the future of the software industry.

Are you neglecting a simple practice that could save your life? Learn how to perform a quick and easy breast self-exam that empowers you to detect potential issues early. This video guide is a must-watch for all women, especially those under 45. Understand why breast self-exams matter Master the step-by-step technique Learn how to "know your normal" Discover tips to make it a habit Recognize when to seek medical attention Join breast cancer survivor Gina Lamanna as she shares her powerful story and teaches you this potentially life-saving skill. Don't wait - your health is in your hands!

Brian uses a specific repeatable framework to convert more opportunities into closed deals.What's his secret? What formulas does he follow? What tactics ring out as repeatable for Brian? He's joining us to share everything from his daily routine to the most impactful tactics he uses on calls. You'll Learn:How top performers manage their dayThe 4 traits of a quota crusherBrian's most impactful sales tactics The Speakers: James Buckley and Brian LaMannaIf you want to catch The Daily Sales Show live, join hereFollow Sell Better to get the latest actionable tactics from sales pros at the top of their gameExplore our YouTube ChannelThank you to our sponsors: Gong and Magical

Charles Lamanna is the Corporate Vice President of Business Apps and Platforms at Microsoft. In this episode, he explores how newly announced Microsoft Copilot capabilities help business leaders do more than boost their personal productivity using AI. They can reinvent their teams and even their entire business. Lamanna also shares how low- and no-code tools are democratizing AI by allowing anyone, not just software developers, to turn their great ideas into products. WorkLab Subscribe to the WorkLab newsletter  

Fun conversations at Midwest Finishers 18 hosted by 10th Planet Black Belt Omar Ocasio at his gym 10th Planet Lombard and streamed live for free on YouTube.

We all know about how common dinosaurs can be in places like Europe, Argentina, the US, China and Mongolia, but they have turned up in dozens and dozens of countries and on every continent, including Antarctica. Unsurprisingly, it's a very tough place to work, it costs a ton of money, and there are not that many dinosaurs to be found, but they are there. Today we are joined by Matt Lamanna of the Carnegie Museum who has spent multiple field seasons on the chilly continent and he tells us about lush forests, tiny dinosaurs, ancient birds and modern penguins. So join us to learn about what is perhaps the last great unexplored area of dinosaurs, the bottom of the world.   Links: SEE TERRIBLE LIZARDS LIVE! https://oldfirestation.org.uk/whats-on/terrible-lizards-podcast/   Matt's website on the project: https://antarcticdinos.org/   Matt's profile at the Carnegie: https://carnegiemnh.org/research/matthew-lamanna/   A short post of Dave's on the Carnegie sauropods, click through the next few posts if you want to see all of their dinosaurs: https://archosaurmusings.wordpress.com/2011/11/10/cargenie-dinosaurs/

I've worked with a bunch of different sellers. Some were good. Some not so much. But one or two were truly next level.They had consistently better results. They brought in bigger deals. They closed accounts no one else could. And they just seemed to "get it" in a different way. They were switched on—you didn't need to tell them what to do. Whatever challenge you threw at them, they found a way. They seemed built just a little bit differently than other people on the team.I've always been curious about what makes those great sellers great.To help answer that question, I sat down with true superstar of the sales world, 5x President's Club winner Brian LaManna, Strategic AE at Gong. Thanks to Our SponsorMany thanks to the sponsor of this episode - Knak. If you don't know them (you should), Knak is an amazing email and landing page builder that integrates directly with your marketing automation platform. You set the brand guidelines and then give your users a building experience that's slick, modern and beautiful. When they're done, everything goes to your MAP at the push of a button. What's more, it supports global teams, approval workflows, and it's got your integrations. Click the link below to get a special offer just for my listeners. Try Knak About Today's Guest Brian LaManna is a Strategic Account Executive at Gong and Founder of Closed Won, where he offers resources and playbooks for sellers. He is a 5x President's Club winner and regularly achieves 200%+ of quota. https://www.linkedin.com/in/brianlamanna/Key Topics[00:00] - Introduction[01:28] - Role of a seller in the revenue process[03:11] - Sales is not convincing[04:03] - Defusing prospect defensiveness[05:48] - When to break the sales process[07:21] - Are good sellers born or made? [09:26] - Attributes of a great seller[11:25] - Developing a “CEO” mindset[13:17] - Cultivating real relationships with customers[16:11] - Mindsets, strategies, and routines [24:18] - Benefits of selling Gong[25:28] - The sales / sales ops relationship[28:53] - How ops can get sellers to cooperate[31:45] - What does Gong's RevOps team do well? [33:43] - Why AEs should always be prospecting[39:02] - Current state of outbound [41:39] - Live example: creating a tailored cold email[44:47] - Personalization vs. relevance[46:45] - How sellers can win at “social selling”Resource LinksClosed Won | Systematizing OutboundLinkedIn Post: Personalization vs. Relevance Learn MoreVisit the RevOps FM Substack for our weekly newsletter: Newsletter

On today's episode of The Route to Networking, Telecom edition we welcome Mark LaManna, former Presidential Communications for the White House Communications Agency. Stay up to date with Mark here: https://www.linkedin.com/in/mark-lamanna-40786b75/Want to stay up to date with new episodes? Follow our LinkedIn page for all the latest podcast updates!Head to: https://www.linkedin.com/company/the-route-to-networking-podcast/Interested in following a similar career path? Why don't you take a look at our jobs page, where you can find your next job opportunity? Head to: www.hamilton-barnes.com/jobs/

In this episode of Rep Matters, hosts Zoya Segelbacher and Caroline Jones chat with Brian LaManna from Gong. Brian shares his journey in sales, starting from his college days to becoming a top performer at Gong. He emphasizes the importance of resilience, learning from every experience, and the value of direct, honest communication in sales. The episode dives into Brian's approach to sales, including his multi-channel prospecting strategy and the significance of writing skills in the sales process. Brian also discusses his side project, "Closed Won," aiming to help sellers enhance their skills, showcasing his dual passion for sales and personal growth.

Drew and Ross Mathews are joined at the news desk by “Ghosts” star Danielle Pinnock to cover today's hottest headlines. Then, it's an all-new “Take Care Up There” and Drew is learning health tips from experts Dr. Suzanne Gilberg-Lenz and Dr. Kameelah Phillips.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today on Journey Map, we're joined by Nancy Crimi-Lamanna, Chief Creative Officer at FCB Canada. In this episode, we talk about her word geek history, the challenges that come with transitioning into leadership, and the valuable work that FCB does with the Canadian Down Syndrome Society.Learn more from Nancy and FCB Canada:Visit FCB Canada:https://fcbtoronto.com/Connect with Nancy:www.linkedin.com/in/nancy-crimi-lamanna-52207311/

Brian LaManna is one of the most popular tech sales LinkedIn influencers, 47k followers at the time of this recording. He is one of the top AEs at Gong, attending presidents club 4x, he reveals his secrets to cold calling, discovery, & sales success. Connect on LinkedIn: Trent Dressel: https://www.linkedin.com/in/trentdressel/ Brian LaManna: https://www.linkedin.com/in/brianlamanna/

Alex Kremer engages with Brian LaManna in an insightful exploration of the tech sales landscape. Brian takes us through his remarkable journey, transitioning from a driven Sales Development Representative to a distinguished leader in sales. Along this journey, he uncovers the pivotal steps and tactics that fueled his professional ascent. Brian provides a treasure trove of knowledge on proficient sales methodologies, underscoring the significance of perpetual learning and the mastery of personal branding within the realm of tech. His narrative, a compelling fusion of ambition, proficiency, and resilience, offers our listeners a distinct viewpoint on navigating and excelling in the dynamic and challenging environment of technology sales.Chapters:00:00:00 - Introduction: Setting the Stage for a Journey in Tech Sales00:01:50 - Meet Brian LaManna: From SDR to Sales Leadership00:03:40 - Brian's Evolution: Navigating the LinkedIn Landscape00:04:45 - Content Creation Impact: Building a Personal Brand00:14:36 - Envisioning the Future: Brian's Career Trajectory00:26:15 - The Power of the Present: Staying Grounded in a Fast-Paced Industry00:30:16 - Defining Moments: Overcoming Challenges in Tech Sales00:36:34 - Farewell Thoughts: Connect with Brian LaMannaConnect With Brian here:LinkedInThanks so much for joining us this week. Want to subscribe to The Rising Leader? Have some feedback you'd like to share? Connect with us on iTunes and leave us a review!Mentioned in this episode: The Arise Immersion

Greetings Cartel! This was a very fun episode chatting with Len Lamanna from the local Toronto band Frail Fragment! We discussed a lot of his musical history, wild stories from his past, the late great Canadian radio DJ Martin Streek & even the scamdemic! Sit back & enjoy this wild ride! Please don't forget to check out their music & crank it up! There's lots of great tunes to enjoy! Visit their website here: https://frailfragment.com/ OR stream their music on most major streaming platforms. Find Len & Frail Fragment on Instagram here: @frailfragment https://instagram.com/frailfragment?igshid=MzMyNGUyNmU2YQ== Please like, share, subscribe and leave a review on #iTunes! Also you can feed Nigel the goat some extra shekels at my patreon if you would be so kind. He will love you for all eternity. Patreon here: patreon.com/redpillcartelpodcast Telegram here: t.me/redpillcartel Instagram here: @redpillcartelpodcast Always feel free to ask to get on the show! Email redpillcartelpod@gmail.com One stop shop for all links: https://linktr.ee/redpillcartelpodcast

Brian is the man! --- Send in a voice message: https://podcasters.spotify.com/pod/show/hampton-dortch/message

Brian is crushing it in tech sales and has been for several years now. A few years ago, he had the opportunity to take a large pay raise and manage a team of sellers. He ended up turning it down because he thought it wasn't the wisest choice for him in the long run. He has the "Learn Before You Earn" mindset better than most! Join 25,000 + others and follow him on LinkedIn: https://www.linkedin.com/in/brianlamanna/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/hampton-dortch/message

FOUR ACTIONABLE TAKEAWAYS Use a "what I heard" slide to show you listened and as a reason to ask further questions. Ask your prospect to rate how they feel about your solution on a scale of 1-10. If you're a 10, are they ready to buy OR can you make the case to move forward? Every day, take a look at your opportunities and consider what you could do today to better your chances with this deal. PATH TO PRESIDENT'S CLUB Senior Mid-Market Account Executive @ Gong Mid-Market Account Executive @ Gong Commercial Account Executive @ Gong Senior Commercial Account Executive @ Gong Enterprise Account Executive @ BrightEdge THE LATEST FROM 30MPC Tactic TV Toolkits & Templates Twitter YouTube THINGS YOU CAN STEAL Prospecting Lavender: Sales Email Frameworks ZoomInfo: 5 Plays, 30MPC Style Woodpecker: Nick's Sales Cadence Orum: 5 Cold Call Objection Talk Tracks Owler: 4 Multi-Channel Prospecting Touchpoints (Try Owler Max) Boomerang: Tactics for Peak Productivity Hireframe: Fast Track your Prospecting Discovery & Demo Clari: How to Sell to the CFO Calendly: Templates & Scripts for Every Sales Meeting Klue: Dismantling Competitors Sales Process Demandbase: 6 Templates to Accelerate Deals Gong: Master Class Qwilr: Multithreading Power Plays Outreach: 1 Sequence to Create and 5 Templates to Close Accord: Business Case Template Prolifiq: Relationship Mapping Playbook Salesloft: Selling to Power ONE ASK You know we feel a bit awkward asking, but if you made it this far, it would mean the world if you joined our newsletter. It will increase your chances of making President's Club by 227%. Okay maybe not, but we'd still really love you for it :)

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Founder Gina Lamanna is not only a fashion stylist and entrepreneur, but also a mother of two girls who triumphed over breast cancer. Her personal journey began at age 41 when, after encountering two false-negative mammograms and a misdiagnosis, she detected her own breast cancer through self-examination. This experience served as the inspiration behind her initiative, The Fondle Project. Gina Lamanna's battle with breast cancer propelled her to channel her love for fashion into a meaningful cause for fellow women. She firmly believes that fashion can play a pivotal role in the recovery of breast cancer survivors. By embracing and celebrating their bodies, these survivors can rediscover their self-assurance, femininity, and sensuality. Lamanna is committed to raising awareness about early detection methods such as regular self-examinations and advocating for oneself. Her goal is to empower younger women to establish a profound connection with their bodies and overall well-being. Within her community, she has brought together resilient women who lead vibrant lives, refusing to let cancer define them. Lamanna acknowledges that cancer's impact knows no bounds and forever alters its survivors. However, she views it as a single chapter in a broader life story that remains under their control. Resources: The Fondle Project Website and Instagram Sonocine in Santa Monica, CA -- Automated Whole-Breast Ultrasound Share Your Story Make Boobs Real Again eBook

Today, I'm so happy to annoounce my episode with Broadway star Janine LaManna. Janine's solo show Black and Gold plays tomorrow night, June 26 at the Green Room 42, and tickets are available here. Tune in today to hear some of the stories of her incredible career, including her appearances in Seussical, Sweet Charity, and Kiss Me, Kate. You won't want to miss this in-depth conversation.

In this exclusive and captivating interview, we delve deep into the remarkable mind of Charles Lamanna, Corporate Vice President of Business Apps & Platform at Microsoft. Join us as we uncover the insights and experiences that have propelled Lamanna, to the forefront of innovation. Discover the driving forces behind Lamanna's relentless pursuit of technological advancement and his passion for empowering developers around the world. Gain valuable insights into Microsoft's transformative initiatives, with Lamanna's expertise as the driving force behind the company's Low Code Application Platform strategy. Explore the challenges and triumphs that have defined Lamanna's career, as he shares invaluable lessons learned along the way. Delve into the future of technology as Lamanna provides a glimpse into the next phase of the developer. This interview is an unmissable opportunity to gain unparalleled access to the visionary mind of Charles Lamanna, gaining inspiration and insights that will leave you captivated and eager to embrace the limitless possibilities of the digital era. Don't miss this engaging conversation.

Ever wondered what it's like to be an Account Executive? Join us in this exciting interview as we take you behind the scenes and explore a typical day in the life of an Account Executive - from the perspective of Brian LaManna - the top AE at Gong.

Rock LaManna is The Deal Flow Guy, a professional matchmaker, quietly bringing independent business owners together with Private Equity groups to create win-win deals.  While his background is in the print and graphic arts industry, Rock has facilitated deals for buyers and sellers in all industries.  Sellers trust Rock because he's on their side, ensuring they get the best deal. Rock is The Seller's Coach.  Buyers respect Rock because he knows dealmaking and guides inexperienced sellers to a successful close.  As CEO of LaManna Consulting Group, Rock's purpose is to assist business owners with their buy, sell, or grow goals. Rock brings synergistic businesses to Private Equity to buy and successfully close the deal. He finds the right buyer for the business owner ready to move on. The right buyer is the one that shares core values and has the funds to make it happen. Lastly, as a proven and 4th generation entrepreneur, Rock is in the unique position to coach business owners to think strategically, construct timelines, and reach growth goals. Rock is an accomplished author, speaker, and podcaster. On his podcast, “The Printer's Edge with Rock LaManna” Rock provides commentary, insight, and personal anecdotes to his audience.  He's been a regular columnist for LN&W for over a decade. He published his first book, “They Named You Right” in 2022, a business memoir that details the early part of his career, managing and selling a family business, along with Rock's Diamonds, accumulated wisdom from over four decades in business. Rock's primary objective is to share his wisdom with business owners. He enjoys hosting live webinars and speaking before audiences whenever the opportunity arises. To Contact Rock Rock LaManna Founder & CEO LaManna Consulting Group 561-543-2323 Rock@RockLaManna.com dealflowguy.com lamannaconsultinggroup.com https://www.linkedin.com/in/rocklamanna/ @RockLaManna YouTube: https://www.youtube.com/channel/UCkRO30aF5LqpnUEivy2uYvQ ************ About the Show The How to Sell a Business Podcast combines nearly 30 years of valuation and exit planning expertise working with business owners. Ed Mysogland has a mission and vision to help business owners understand the value of their business and make it a salable asset. Most of the small business owner's net worth is locked in the company, and to unlock it, a business owner has to sell it. Unfortunately, the odds are against business owners that they won't be able to sell their companies because they don't know what creates a saleable asset. Ed interviews experts who help business owners prepare, build, preserve, and one-day transfer value with the sale of the business. ************ For past guests, please visit https://www.howtosellabusinesspocast.com/ Follow Ed: Connect on LinkedIn: https://www.linkedin.com/in/edmysogland/ Twitter: twitter.com/edmyso Instagram: instagram.com/howtosellabusinesspodcast Facebook: facebook.com/howtosellabusinesspodcast

Every so often, a new brocstar bursts onto the scene and just blows our PLANTSTRONG socks off with their passion, personality, and unique approach to plant-based eating. Today's guest, Max LaManna, is one of those people. He has over a million followers on social media and, for one year, Max asked his audience which foods they threw away the most. Using the tens of thousands of responses, he narrowed down a list of thirty of the most commonly wasted ingredients and those were the inspiration for his new book, You Can Cook This! We're talking about peppers, potatoes, onions, beets, grains, carrots, leafy greens, and bananas - all of the things we love most here at PLANTSTRONG. Max and Rip dig into some of these fun recipes today and talk about how to prepare and store your food to maximize its freshness and extend its shelf life. No more throwing away those perfectly good banana peels or potatoes, let's put them to use! Max inspired all of us at PLANTSTRONG and we know he will inspire and transform the way you cook, eat, and save your food.   Episode Highlights 8:20 Growing up in the food industry and thinking his parents were “foodies” 10:35 How he went from zero followers to over a million talking about zero-waste 16:10 Wait. We waste HOW much food each year here in the US? 17:00 How his audience inspired his latest book, You Can Cook This! 19:00 Max shares his story of going vegan twice 26:15 Tips for food storage and avoiding waste for all types of food Don't fill up the fridge too full! You can put tomatoes in the fridge to extend their shelf life Why do you never want to store potatoes and onions together? The trick for using and cleaning bell peppers Freezing asparagus, leafy greens, and other veggies are a-ok. Take a look at what other veggies are in the freezer section at the grocery 44:45 A Deep Dive into the Recipes of You Can Cook This! 1:25:00 Rapid Fire Questions with Rip   Episode Resources Watch the Episode on YouTube Max LaManna's Website with Recipes and Links to all of his Social Channels and Resources Follow Max on Instagram @maxlamanna Join our PLANTSTRONG Sedona Retreat - October 9-14, 2023 To stock up on the best-tasting, most convenient, 100% PLANTSTRONG foods, including our cereals, granolas, pizza kits, broths and soups, check out all of our PLANTSTRONG products HERE. Give us a like on the PLANTSTRONG Facebook Page and check out what being PLANSTRONG is all about. We always keep it stocked full of new content and updates, tips for healthy living, delicious recipes, and you can even catch me LIVE on there! We've also got an Instagram! Check us out and share your favorite PLANTSTRONG products and why you love it! Don't forget to tag us using #goplantstrong

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Today we welcome back musician and composer Len Lamanna! As an artist, Len's done some edgy work with his hard core riffs and powerful jams. He's recently taken his skills to composing features and his newest work on The Last Slay Ride resonates his gift to new heights! Join us on a conversation about composing for film, his influences, procrastination, scary movies and how important self care is to the soul! Music tells its own stories and is a major part of multimedia storytelling so sit back and enjoy our discussion with our friend Len Lamanna!Website:https://frailfragment.com/Speak with Coach Rick:thecoachrick@gmail.comBuzzsprout - Let's get your podcast launched! Start for FREE Entrepreneur Swag Shop! Get your swag! Identity is about being who you are meant to be! Use coupon code AROUNDTHEREEL & save 15%!Launch Your Business With Printful! Start Selling Merchandise Today! Use The Around The Reel Link And Try It Out For Free!Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showCheck out our website!www.cccentertainmentgroup.comFacebookhttps://www.facebook.com/AroundTheReelPodcast/

Ep 214 - CEO of LaManna Patrick LaManna as we discuss the future for a loved family food brand LaManna is an Australian Family Owned and Operated business, based at Essendon Fields Airport in Melbourne It sits at Hangar 89 in a 10,000 sqm food shopping emporium that is without a doubt, one of the best food retail experiences in Australia. As we will learn today, Lamanna is a third-generation family business, with humble beginnings, that has been thoughtfully positioned into the leader in food retail.  Today we will learn about the journey of LaManna, an upcoming recruitment weekend, and it's plans for the future, so it's a privilege to sit down with the CEO Patrick LaManna on this week's podcast.   In this podcast we discuss: -What is the history of LaManna Supermarket brand in Victoria is. -How Patrick started out in the business and became the CEO. -What the great things are about running a family business like LaManna. -Why the business focuses so much on having hospitality as the cornerstone of the retail experience. -The LaManna recruitment weekend on the 5th and 6th of November, and why it is important for the business. -What plans the group has in the next 12-24 months and how are they are planning to change an already fantastic food retail experience. Please find our guest information here: Website: https://www.lamannas.com.au/ (https://www.lamannas.com.au/) Instagram: https://www.instagram.com/lamannamelbourne/ (https://www.instagram.com/lamannamelbourne/) Recruitment Booking Link: https://calendly.com/d/d2b-8t8-2qr (https://calendly.com/d/d2b-8t8-2qr) Please find us here at POH: Website: https://principleofhospitality.com/ (https://principleofhospitality.com/) Instagram: https://www.instagram.com/principle_of_hospitality/ (https://www.instagram.com/principle_of_hospitality/) Mentioned in this episode: Free Brand Strategy Session with Principle Design Principle Design is making brands happen in cafes, restaurants, bars, and venues by crafting experiences that give customers a reason to choose you. They can help you deliver memorable culinary experiences through innovative design and authentic brand storytelling. If your operation is in need of branding, a website, menu, coaster, uniform, signage or packaging design or even social media services, then Principle Design is your next contact. For a limited time only, Principle Design is offering the POH community free brand strategy sessions! Visit our bio for more information. https://principle-of-hospitality.captivate.fm/free-brand-strategy-session- (Principle Design ) Free Brand Strategy Session with Principle Design Principle Design is making brands happen in cafes, restaurants, bars, and venues by crafting experiences that give customers a reason to choose you. They can help you deliver memorable culinary experiences through innovative design and authentic brand storytelling. If your operation is in need of branding, a website, menu, coaster, uniform, signage or packaging design or even social media services, then Principle Design is your next contact. For a limited time only, Principle Design is offering the POH community free brand strategy sessions! Visit our bio for more information. https://principle-of-hospitality.captivate.fm/free-brand-strategy-session- (Principle Design )

In this episode, Antonia and Andrew a selection of articles from the September 21, 2022 issue of JBJS, along with an added dose of entertainment and pop culture. Listen at the gym, on your commute, or whenever your case is on hold! Top of the Pile What’s New in Hip Replacement, by Morgan Host Perspectives of High-Income Country Orthopaedic Resident Rotations in Low and Middle-Income Countries, by Roberts et al. Deep Learning and Imaging for the Orthopaedic Surgeon. How Machines “Read” Radiographs, by Hill et al. What's Important: Dealing with Gun Violence, by Lachiewicz New Beginnings and Revealing Invisible Identities, by Bellamy et al. Diversity and Inclusion in Orthopaedic Surgery from Medical School to Practice, by Lamanna et al. Headlines Spontaneous Lumbar Curve Correction Following Vertebral Body Tethering of Main Thoracic Curves, by Catanzano et al. Applying Deep Learning to Establish a Total Hip Arthroplasty Radiography Registry. A Stepwise Approach, by Rouzrokh et al. Your Case is On Hold Serum Glucose Variability Increases the Risk of Complications Following Aseptic Revision Hip and Knee Arthroplasty, by Goh et al. Honorable Mention Defining Minimally Important Differences in Functional Outcomes in Musculoskeletal Oncology, by Gazendam et al.